Drug Profile
Research programme: biodefence vaccines - GenPhar
Alternative Names: Biodefense vaccines - GenPharLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GenPhar
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Influenza virus infections; Severe acute respiratory syndrome; Viral haemorrhagic fevers
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome in USA (Parenteral)